| Trial ID: | L2941 |
| Source ID: | NCT02911792
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
|
| Acronym: |
Hyper
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02911792/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Metformin|DRUG: Glipizide 5 MG
|
| Outcome Measures: |
Primary: GFR (Glomerular Filtration Rate) Change After Treatment, Change from baseline in GFR after treatment from baseline to 4 months, 4 months |
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
72
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-12-20
|
| Completion Date: |
2023-07-11
|
| Results First Posted: |
2023-11-30
|
| Last Update Posted: |
2023-11-30
|
| Locations: |
University Health Systems Texas Diabetic Institute, San Antonio, Texas, 78207, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02911792
|
